This year's Memorial Sloan Kettering Cancer Center (MSK) Health Equity Conference brought together experts from various fields, institutions, and specialties to speak about ways we can improve health equity for communities that are underserved due to limited access to healthcare. Through diversity of perspectives and expertise, the conference helped highlight the many different ways one can improve health equity in their own practice and institution. Swipe through to view a few images from the event.
Memorial Sloan Kettering Cancer Center
Hospitals and Health Care
New York, NY 240,773 followers
About us
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
- Website
-
http://www.mskcc.org
External link for Memorial Sloan Kettering Cancer Center
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 1884
Locations
Employees at Memorial Sloan Kettering Cancer Center
Updates
-
Happening now: Join breast oncologist Dr. Pedram Razavi as he presents new research from his team, including lead author and computational biologist Enrico Moiso, on metastatic breastcancer at the San Antonio Breast Cancer Symposium. #SABCS24
-
-
Highlights from the American Society of Hematology Annual Meeting include practice-changing insights for patients with multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Learn more about research from MSK experts, including Dr. Urvi Shah, Dr. Megan Thompson, Dr. Leora Boussi, and more: https://bit.ly/49EbS35
-
-
#SABCS24: Join postdoctoral researcher Dr. Avantika Gupta for her presentation on "APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer" today at 11:30am CT at the San Antonio Breast Cancer Symposium.
-
-
Research advances in lymphoma, leukemia, and multiple myeloma were presented at the American Society of Hematology Annual Meeting by researchers at Memorial Sloan Kettering Cancer Center (MSK), including hematologist-oncologist Dr. Alison Moskowitz, hematologic-oncologist Dr. Susan De Wolf, and myeloma specialist Dr. Kylee Maclachlan. Learn more about their research: https://bit.ly/4iA3gif
-
-
“These results will change how many breast cancers are treated,” says Dr. Komal Jhaveri, a medical breast oncologist at Memorial Sloan Kettering Cancer Center (MSK). Results from a new clinical trial show an experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to standard therapy. The drug, imlunestrant, was especially effective when combined with a second drug, abemaciclib (Verzenio®). Learn more about Dr. Jhaveri's research: https://bit.ly/4f98AG9
-
-
#SABCS24: Join breast medical oncologist Dr. Neil Iyengar for his presentation on fat loss and metabolic improvement and cancer risk today at 12pm CT at the San Antonio Breast Cancer Symposium.
-
-
Researchers at Memorial Sloan Kettering Cancer Center (MSK), University of British Columbia (UBC), BC Cancer, and Harvard Medical School have pinpointed what could be the early genetic origins of breast cancer: cancer-like mutations appearing in the cells of healthy women. Learn more about why this study raises important new questions about the nature of breast cancer development: https://bit.ly/4gqADlH
-
-
#ASH24: Join Dr. Meghan Thompson, a leukemia specialist at Memorial Sloan Kettering Cancer Center (MSK), for her presentation on "Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)" today at 4:45pm PT at the American Society of Hematology Annual Meeting. Learn more: https://bit.ly/3OKnxnB
-
-
#ASH24: Join myeloma specialist Dr. Kylee Maclachlan for her presentation on "Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry" today at 11:15am at the American Society of Hematology Annual Meeting. Learn more: https://bit.ly/3D6M43u
-